HROWNasdaqPharmaceutical PreparationsFiscal year ends December 31
HARROW, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$27.68+0.40 (+1.47%)
Close on Oct 19, 2026
- Market cap
- $1.03B
- P/E (TTM)
- –
- Dividend yield
- –
HARROW, INC. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Branded | $212.51M | $198.68M | $195.76M | $167.97M | $144.94M | $130.03M | $116.12M | $86.18M | $72.12M | – | $50.26M | – | 77.1% | +46.6% |
| ImprimisRx [Member] | – | – | $76.55M | $82.07M | $82.72M | $82.83M | $83.50M | $82.96M | $82.03M | – | $79.94M | – | – | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $275.21M | $268.29M | $271.91M | $249.12M | $226.64M | $211.86M | $198.62M | $168.04M | $150.83M | $131.50M | $117.45M | $101.90M | 99.9% | +21.4% |
| VEVYE | $98.87M | $88.12M | $88.69M | $78.75M | $61.31M | $46.98M | $28.06M | – | – | – | – | – | 35.9% | +61.3% |
| IHEEZO | $75.26M | $77.98M | $81.35M | $68.27M | $59.25M | $52.20M | $49.30M | $37.05M | $30.09M | – | $20.62M | – | 27.3% | +27.0% |
| Other branded products | $38.00M | $32.20M | $25.33M | $20.10M | $23.45M | $29.92M | $37.84M | $32.73M | $29.08M | – | $15.13M | – | 13.8% | +62.0% |
| Other revenues | $386.00K | $381.00K | $394.00K | $922.00K | $1.02M | $1.00M | $995.00K | $1.10M | $3.32M | $7.18M | $12.75M | $12.27M | 0.1% | -62.1% |
| Other Revenue [Member] | – | – | $394.00K | $852.00K | $939.00K | $922.00K | $915.00K | $2.54M | $4.27M | – | $12.75M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Harrow's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.